|Bid||5.3500 x N/A|
|Ask||5.4500 x N/A|
|Day's Range||4.3400 - 4.3400|
|52 Week Range||2.6200 - 5.7500|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 08, 2023 - May 12, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Delcath Systems Inc (NASDAQ: DCTH) shares are rising over 23% as FDA accepted its new drug application resubmission for HEPZATO Kit (melphalan hydrochloride for Injection/Hepatic Delivery System) seeking approval for unresectable hepatic-dominant metastatic ocular melanoma (mOM). The FDA also communicated to Delcath that they consider the submission a complete class 2 response, and the PDUFA date for the resubmission is August 14, 2023. The resubmission is in response to the FDA's September 12,
Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2022.
Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that the Company has signed securities purchase agreements with certain healthcare-focused institutional investors that will provide up to $85 million in gross proceeds to Delcath through a private placement that includes initial upfront funding of $25 million.